Skip to Content

WPI 2233 (Tamoxifen Citrate 20 mg)

Pill with imprint WPI 2233 is White, Round and has been identified as Tamoxifen Citrate 20 mg. It is supplied by Watson Pharmaceuticals, Inc..

Tamoxifen is used in the treatment of breast cancer, adjuvant; breast cancer; breast cancer, male; breast cancer, metastatic; breast cancer, palliative (and more), and belongs to the drug classes hormones/antineoplastics, selective estrogen receptor modulators. There is positive evidence of human fetal risk during pregnancy. Tamoxifen 20 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 2233

Tamoxifen citrate 20 mg WPI 2233
Tamoxifen citrate 20 mg WPI 2233
Tamoxifen citrate 20 mg WPI 2233 Front
Tamoxifen citrate 20 mg WPI 2233 Back
Tamoxifen citrate 20 mg WPI 2233
Tamoxifen citrate 20 mg WPI 2233

Tamoxifen Citrate

Imprint:
WPI 2233
Strength:
20 mg
Color:
White
Shape:
Round
Availability:
Prescription only
Drug Class:
Hormones/antineoplastics
Selective estrogen receptor modulators
Pregnancy Category:
D - Positive evidence of risk
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Watson Pharmaceuticals, Inc.
Inactive Ingredients:
croscarmellose sodium
lactose monohydrate
magnesium stearate
microcrystalline cellulose
pregelatinized corn starch
Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide